Nevertheless, although our findings indicate that CD38 acts via different TME cells in different tissues and cancer types, it may still act via common pathway(s) e.g., increased NAD+ levels and/or reduced CD38 metabolites levels e.g., NAADP. Here, CD38 is linked to cancer.